A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

PHASE3

Phase

NOT_YET_RECRUITING

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: TQB2102 Injection
DRUG: Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.